Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.

This study aims to evaluate the efficacy of genotype-informed Bayesian dosing of tacrolimus in optimising drug exposure among paediatric solid organ transplant recipients. By tailoring tacrolimus dosage based on individual genetic makeup and using Bayesian modeling to predict drug levels, the researchers hope to increase the likelihood of achieving therapeutic drug concentrations while minimising the risk of adverse events associated with subtherapeutic or supratherapeutic exposure.

NCT Number	NCT06529536
Lead Sponsor	Murdoch Childrens Research Institute
Conditions	Solid Organ Transplant
Enrollment	45 participants
Start Date	2024-08-05
Primary Completion	2027-08 (estimated)
Study Completion	2027-08-02 (estimated)
Updated on ClinicalTrials.gov	2026-02-25